15 Jan 2021 16:00
GlaxoSmithKline plc (the 'Company')
Â
Transaction notification
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr N Hirons | |||
b) | Position/status | SVP, Global Ethics & Compliance | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 13 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Â
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms S Jackson | |||
b) | Position/status | SVP, Global Communications & CEO Office | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 2 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr D Jackson | |||
b) | Position/status | PCA of Ms S Jackson (SVP, Global Communications & CEO Office) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 1 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms V Whyte | |||
b) | Position/status | Company Secretary | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 35 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Mr I Whyte | |||
b) | Position/status | PCA of Ms V A Whyte (Company Secretary) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 1,052 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Â
1. | Details of PDMR/person closely associated with them ('PCA') | ||||
a) | Name | Ms D Connor | |||
b) | Position/status | PCA of Mr R G Connor (President, Global Vaccines) | |||
c) | Initial notification/ amendment | Initial notification | |||
2. | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | ||||
a) | Name | GlaxoSmithKline plc | |||
b) | LEI | 5493000HZTVUYLO1D793 | |||
3. | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted | ||||
a) | Description of the financial instrument | Ordinary shares of 25 pence each ('Ordinary Shares') ISIN: GB0009252882 Â | |||
b) | Nature of the transaction | Acquisition of Ordinary Shares following the re-investment of dividends paid to shareholders on 14 January 2021. | |||
c) | Price(s) and volume(s) | Â | Price(s) | Volume(s) | Â |
 | £13.8802 | 542 |  | ||
 |  |  |  | ||
d) | Aggregated information   | N/A (single transaction) | |||
Aggregated volume Price | Â | ||||
e) | Date of the transaction | 2021-01-14 | |||
f) | Place of the transaction  | London Stock Exchange (XLON) | |||
Â
Glaxosmithkline (GSK)